British molecular gastrointestinal diagnostics company for early diagnosis of esophageal cancer (EndoSign device).
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series B Cyted Health raised over €37 million in a Series B led by EQT Life Sciences and Advent Life Sciences for the US commercial expansion of its early esophageal cancer diagnostics. | $42.9M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.